<DOC>
	<DOCNO>NCT01511926</DOCNO>
	<brief_summary>The common pain-relievers used patient rheumatic disorder call non-steroidal anti-inflammatory drug ( NSAIDs ) . These drug effective well document , cause ulcer gastrointestinal side effect . Vimovo™ tablet contain naproxen ( NSAID ) gastroprotective agent call esomeprazole . Patients rheumatic disorder , risk develop gastrointestinal side effect , low dos naproxen NSAID treatment consider sufficient , could use tablet . The regulatory authority many European country approve use Vimovo™ , would like understand various factor influence doctor ' decision prescribe tablet characterize patient receive . The aim study answer question .</brief_summary>
	<brief_title>Descriptive Study Patients Treated With Vimovo™ , Including Registration Physicians ' Prescribing Patterns</brief_title>
	<detailed_description>European study patient osteoarthritis , rheumatoid arthritis , ankylose spondylitis gastrointestinal risk : A retrospective , non-interventional study Vimovo™ prescribing pattern</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<criteria>Diagnosis arthritic disorder ( osteoarthritis , rheumatoid arthritis ankylose spondylitis ) Risk develop gastrointestinal ulcer Already prescribe Vimovo Participation interventional drug study time Vimovo™ prescribe Patients start Vimovo first 3 month countryspecific launch date Patients start Vimovo study site initiate ( order avoid influence prescribe decision recruitment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Vimovo™ treat patient prescribe pattern</keyword>
	<keyword>Risk gastrointestinal side effect</keyword>
</DOC>